Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic
Copyright © 2023 Elsevier Ltd. All rights reserved..
In the last decade, investigators have put significant efforts to develop several diagnostic and therapeutic strategies against cancer. Many novel nanoplatforms, including lipidic, metallic, and inorganic nanocarriers, have shown massive potential at preclinical and clinical stages for cancer diagnosis and treatment. Each of these nano-systems is distinct with its own benefits and limitations. The need to overcome the limitations of single-component nano-systems, improve their morphological and biological features, and achieve multiple functionalities has resulted in the emergence of hybrid nanoparticles (HNPs). These HNPs integrate multicomponent nano-systems with diagnostic and therapeutic functions into a single nano-system serving as promising nanotools for cancer theragnostic applications. Chitosan (CS) being a mucoadhesive, biodegradable, and biocompatible biopolymer, has emerged as an essential element for the development of HNPs offering several advantages over conventional nanoparticles including pH-dependent drug delivery, sustained drug release, and enhanced nanoparticle stability. In addition, the free protonable amino groups in the CS backbone offer flexibility to its structure, making it easy for the modification and functionalization of CS, resulting in better drug targetability and cell uptake. This review discusses in detail the existing different oncology-directed CS-based HNPs including their morphological characteristics, in-vitro/in-vivo outcomes, toxicity concerns, hurdles in clinical translation, and future prospects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:326 |
|---|---|
| Enthalten in: |
Carbohydrate polymers - 326(2023) vom: 15. Feb., Seite 121644 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nair, Rahul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9012-76-4 |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.carbpol.2023.121644 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366327674 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366327674 | ||
| 003 | DE-627 | ||
| 005 | 20231227141203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carbpol.2023.121644 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM366327674 | ||
| 035 | |a (NLM)38142105 | ||
| 035 | |a (PII)S0144-8617(23)01109-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nair, Rahul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a In the last decade, investigators have put significant efforts to develop several diagnostic and therapeutic strategies against cancer. Many novel nanoplatforms, including lipidic, metallic, and inorganic nanocarriers, have shown massive potential at preclinical and clinical stages for cancer diagnosis and treatment. Each of these nano-systems is distinct with its own benefits and limitations. The need to overcome the limitations of single-component nano-systems, improve their morphological and biological features, and achieve multiple functionalities has resulted in the emergence of hybrid nanoparticles (HNPs). These HNPs integrate multicomponent nano-systems with diagnostic and therapeutic functions into a single nano-system serving as promising nanotools for cancer theragnostic applications. Chitosan (CS) being a mucoadhesive, biodegradable, and biocompatible biopolymer, has emerged as an essential element for the development of HNPs offering several advantages over conventional nanoparticles including pH-dependent drug delivery, sustained drug release, and enhanced nanoparticle stability. In addition, the free protonable amino groups in the CS backbone offer flexibility to its structure, making it easy for the modification and functionalization of CS, resulting in better drug targetability and cell uptake. This review discusses in detail the existing different oncology-directed CS-based HNPs including their morphological characteristics, in-vitro/in-vivo outcomes, toxicity concerns, hurdles in clinical translation, and future prospects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer theragnostic | |
| 650 | 4 | |a Chitosan | |
| 650 | 4 | |a Drug targeting | |
| 650 | 4 | |a Hybrid nanoparticle | |
| 650 | 4 | |a Photothermal therapy | |
| 650 | 7 | |a Chitosan |2 NLM | |
| 650 | 7 | |a 9012-76-4 |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Paul, Priti |e verfasserin |4 aut | |
| 700 | 1 | |a Maji, Indrani |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ujala |e verfasserin |4 aut | |
| 700 | 1 | |a Mahajan, Srushti |e verfasserin |4 aut | |
| 700 | 1 | |a Aalhate, Mayur |e verfasserin |4 aut | |
| 700 | 1 | |a Guru, Santosh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Pankaj Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Carbohydrate polymers |d 1994 |g 326(2023) vom: 15. Feb., Seite 121644 |w (DE-627)NLM082819491 |x 1879-1344 |7 nnns |
| 773 | 1 | 8 | |g volume:326 |g year:2023 |g day:15 |g month:02 |g pages:121644 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.carbpol.2023.121644 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 326 |j 2023 |b 15 |c 02 |h 121644 | ||